This trial is active, not recruiting.

Condition malignant melanoma
Treatment cancervax vaccine (canvaxin)
Phase phase 3
Sponsor CancerVax Corporation
Trial size 1118 participants
Trial identifier NCT00052130, CV-MMAIT-3-001, JWCI-MC-3-001A, NCT00004130


This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double-blind
Primary purpose treatment

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

- Must have Stage III melanoma - Must have had all clinically-detectable disease surgically removed - Cannot be taking any medications, or undergoing any therapies which compromise the functioning of your immune system (ie. Some corticosteroids, and certain types of radiation therapy) - Cannot have HIV or Hepatitis A, B, or C

Additional Information

Official title Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma
Trial information was received from ClinicalTrials.gov and was last updated in June 2005.
Information provided to ClinicalTrials.gov by CancerVax Corporation.